We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
Read MoreHide Full Article
Charles River’s (CRL - Free Report) dull Cell Supply business might dampen top-line growth. The global business environment continues to be challenging for the company. The stock currently carries a Zacks Rank #4 (Sell).
Over the past year, Charles River has been underperforming its industry. The stock has declined 44.4% compared with the industry’s 28.8% plunge. A revenue decline in the CDMO business as well as a challenging prior-year comparison for the Biologics Testing and Microbial Solutions businesses in the second quarter dragged Manufacturing Solutions revenues down. The Manufacturing segment's operating margin declined 460 basis points to 28.6% as a result of the expense escalation within the CDMO business.
The company’s cell supply business has been facing issues related to donor access. The cell supply business, including the HemaCare and Cellero, continued to be impacted by constraints on donor availability, which failed to recover completely from COVID-related restrictions.
Foreign exchange is a major headwind for Charles River as a considerable percentage of its revenues come from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets.
In Q2, the impact of foreign currency translation reduced reported revenue growth by 3.4%. Further, Charles River has also reduced its reported revenue growth guidance by 450 basis points to reflect unfavorable movements in foreign currency translation.
Charles River Laboratories International, Inc. Price
The significant slash in 2022 guidance, reflecting headwinds associated with the CDMO business, foreign exchange due to the strengthening U.S. dollar, and interest expense due to the rising interest rate environment, increase concerns.
On a positive note, Charles River exited the second quarter of 2022 with better-than-expected earnings. The results highlighted 9.5% organic revenue growth, driven by strength across the DSA and Research Models and Services RMS business segments.
Within DSA, the company continued to benefit from strong sustained business trends. This segment reported 12.9% organic revenue growth in the second quarter of 2022. The DSA organic growth rate improved nearly 340 basis points from the first-quarter level and reached the low double-digit range. This was driven by the Safety Assessment business that continued to benefit from strong business trends such as higher pricing and increased demand.
Within RMS, organic revenue growth was driven by strong demand and meaningful price increases in the Research Models business in North America, as well as for Global Research Models Services, particularly Insourcing Solutions and GEMS. In the second quarter, RMS revenues increased 8.5% organically year over year, in line with the company’s high single-digit outlook for 2022. Organic revenue growth was driven by strong demand and meaningful price increases in the Research Models business in North America, as well as for Global Research Models Services, particularly Insourcing Solutions and GEMS.
Stocks to Consider
Some better-ranked stocks in the broader medical space areAMN Healthcare Services, Inc. (AMN - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
AMN Healthcarehas gained 7.3% against the industry’s 28.9% fall in the past year.
Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.6%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%.
Patterson Companies has gained 3.6% against the industry’s 6.3% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.9%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 80.8% against the industry’s 6.3% fall over the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Charles River (CRL) Business Hurt by Macro and FX Headwinds
Charles River’s (CRL - Free Report) dull Cell Supply business might dampen top-line growth. The global business environment continues to be challenging for the company. The stock currently carries a Zacks Rank #4 (Sell).
Over the past year, Charles River has been underperforming its industry. The stock has declined 44.4% compared with the industry’s 28.8% plunge. A revenue decline in the CDMO business as well as a challenging prior-year comparison for the Biologics Testing and Microbial Solutions businesses in the second quarter dragged Manufacturing Solutions revenues down. The Manufacturing segment's operating margin declined 460 basis points to 28.6% as a result of the expense escalation within the CDMO business.
The company’s cell supply business has been facing issues related to donor access. The cell supply business, including the HemaCare and Cellero, continued to be impacted by constraints on donor availability, which failed to recover completely from COVID-related restrictions.
Foreign exchange is a major headwind for Charles River as a considerable percentage of its revenues come from outside the United States. The strengthening of the euro and some other developed market currencies has constantly been hampering the company’s performance in the international markets.
In Q2, the impact of foreign currency translation reduced reported revenue growth by 3.4%. Further, Charles River has also reduced its reported revenue growth guidance by 450 basis points to reflect unfavorable movements in foreign currency translation.
Charles River Laboratories International, Inc. Price
Charles River Laboratories International, Inc. price | Charles River Laboratories International, Inc. Quote
The significant slash in 2022 guidance, reflecting headwinds associated with the CDMO business, foreign exchange due to the strengthening U.S. dollar, and interest expense due to the rising interest rate environment, increase concerns.
On a positive note, Charles River exited the second quarter of 2022 with better-than-expected earnings. The results highlighted 9.5% organic revenue growth, driven by strength across the DSA and Research Models and Services RMS business segments.
Within DSA, the company continued to benefit from strong sustained business trends. This segment reported 12.9% organic revenue growth in the second quarter of 2022. The DSA organic growth rate improved nearly 340 basis points from the first-quarter level and reached the low double-digit range. This was driven by the Safety Assessment business that continued to benefit from strong business trends such as higher pricing and increased demand.
Within RMS, organic revenue growth was driven by strong demand and meaningful price increases in the Research Models business in North America, as well as for Global Research Models Services, particularly Insourcing Solutions and GEMS. In the second quarter, RMS revenues increased 8.5% organically year over year, in line with the company’s high single-digit outlook for 2022. Organic revenue growth was driven by strong demand and meaningful price increases in the Research Models business in North America, as well as for Global Research Models Services, particularly Insourcing Solutions and GEMS.
Stocks to Consider
Some better-ranked stocks in the broader medical space areAMN Healthcare Services, Inc. (AMN - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 3.2%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.7%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcarehas gained 7.3% against the industry’s 28.9% fall in the past year.
Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.6%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%.
Patterson Companies has gained 3.6% against the industry’s 6.3% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.9%. MCK’s earnings surpassed estimates in three of the trailing four quarters and missed the same in one, the average beat being 13%.
McKesson has gained 80.8% against the industry’s 6.3% fall over the past year.